Tulane University: Molecularly Targeted Radiation Therapy Extends Survival for Patients With Advanced Prostate Cancer
June 04, 2021
June 04, 2021
NEW ORLEANS, Louisiana, June 4 (TNSRes) -- Tulane University issued the following news release:
A new cancer treatment that uses engineered radioactive molecules to target prostate cancer cells and inhibit tumor growth extended survival for patients with advanced prostate cancer, according to newly announced results of the VISION trial.
The international phase III clinical trial, which was co-led by Tulane University medical oncologist Dr. Oliver Sartor, is the first to . . .
A new cancer treatment that uses engineered radioactive molecules to target prostate cancer cells and inhibit tumor growth extended survival for patients with advanced prostate cancer, according to newly announced results of the VISION trial.
The international phase III clinical trial, which was co-led by Tulane University medical oncologist Dr. Oliver Sartor, is the first to . . .